Sign in

CIK 0000072444

  • Accelerated filer
  • Smaller reporting company

Vaxart, Inc.

Sign in to watch
Ticker
VXRT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
591212264
Phone
+1 650-550-3500
Business address
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Grant or award Director acquired 2,500 shares (grant or award)
  5. 4 Derivatives Options or other derivatives
  6. 4 Open-market buy Director bought 35,000 shares at $2.20 ($76,892)
  7. 4/A Open-market buy Director bought 70,000 shares at $2.03 ($142,100)
  8. 4 Open-market buy Director bought 70,000 shares at $1.99 ($139,300)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Grant or award Director acquired 7,500 shares (grant or award)
  14. 4 Open-market buy CEO bought 20,000 shares at an average $2.28 ($45,689)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Grant or award Vice Chairmen acquired 40,000 shares (grant or award)
  18. 4 Open-market buy EVP, Corporate Dev & Strategy bought 10,000 shares at $2.86 ($28,600)
  19. 4 Open-market buy EVP, Corporate Dev & Strategy bought 5,000 shares at an average $2.81 ($14,026)
  20. 4 Open-market buy CEO & President bought 32,031 shares at an average $2.99 ($95,692)

Page 13 of 28 · 550 filings